Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modeling rectal cancer to advance neoadjuvant precision therapy.

International journal of cancer - 1 Sept 2020

Janakiraman Harinarayanan, Zhu Yun, Becker Scott A, Wang Cindy, Cross Ashley, Curl Emily, Lewin David, Hoffman Brenda J, Warren Graham W, Hill Elizabeth G, Timmers Cynthia, Findlay Victoria J, Camp Ernest R

Abstract excerpt

Progress in rectal cancer therapy has been hindered by the lack of effective disease-specific preclinical models that account for the unique molecular profile and biology of rectal cancer. Thus, we developed complementary patient-derived xenograft (PDX) and subsequent in vitro tumor organoid (PDTO) platforms established from preneoadjuvant therapy rectal cancer specimens to advance personalized care for rectal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cetuximab
Share to Fluorouracil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterografts

Share to Neoadjuvant Therapy

Share to Organoids

Share to Precision Medicine

Share to Rectal Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 31989583
DOI: 10.1002/ijc.32876

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modeling rectal cancer to advance neoadjuvant precision therapy.PMID 31989583Read ↗

Modeling colorectal cancer: A bio‐resource of 50 patient‐derived organoid linesSemantic proximity Read ↗

Leveraging a Patient-Derived Tumoroid Platform for Precision Radiotherapy: Uncovering DNA Damage Repair Inhibitor-Mediated Radiosensitization and Therapeutic Resistance in Rectal CancerSemantic proximity Read ↗

XENTURION, a multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients for population-level translational oncologySemantic proximity Read ↗

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.Semantic proximity Read ↗

Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity.Semantic proximity Read ↗

Rectal cancer.Semantic proximity Read ↗

Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor.Semantic proximity Read ↗

Unveiling radiobiological traits and therapeutic responses of BRAFV600E-mutant colorectal cancer via patient-derived organoidsSemantic proximity Read ↗

Cell Viability or Image-based Analysis: Evaluation of Dose Response of Patient-derived Cancer Organoids to IrradiationSemantic proximity Read ↗

A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells.Semantic proximity Read ↗

Cell Viability or Image-based Analysis: Evaluation of Dose Response of Patient- derived Cancer Organoids to Irradiation Running Title: Dose Response of Cancer Organoids to IrradiationSemantic proximity Read ↗

Patient Derived Organoids Confirm That PI3K/AKT Signalling Is an Escape Pathway for Radioresistance and a Target for Therapy in Rectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.